NCT03294863

Brief Summary

The purpose of this study is to determine whether the use of the embrace device after repair of linear cutaneous surgery wounds improves scar cosmesis.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
49

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 15, 2017

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

September 22, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 27, 2017

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 8, 2025

Completed
6 months until next milestone

Results Posted

Study results publicly available

June 10, 2026

Completed
Last Updated

June 10, 2026

Status Verified

June 1, 2026

Enrollment Period

4.7 years

First QC Date

September 22, 2017

Results QC Date

February 11, 2026

Last Update Submit

June 8, 2026

Conditions

Keywords

ScarCosmesisEmbrace DeviceSplit WoundWound ClosureCutaneous Wound

Outcome Measures

Primary Outcomes (2)

  • Physician Observer Scar Assessment Score (POSAS)

    The Patient Observer Scar Assessment Score (POSAS) will be used to compare the cosmetic appearance of scars in the area treated with the device versus the area that was not treated. The POSAS measures scar quality in all types of scars by evaluating visual (e.g. color), tactile (e.g. pliability) and sensory (e.g. itch) characteristics of the scar from the perspective of the observer and patients. Scores for each subscale range from 1 to 10, for a sum score range from 6 to 60. Low scores indicate better outcomes.

    3 months

  • Width of the Scar

    The width of the scar on both sides will also be measured and recorded 1 cm from midline on both sides of the scar

    3 months

Study Arms (2)

Embrace Scar Therapy Device

EXPERIMENTAL

16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive will be applied to 1/2 of the cutaneous wound

Device: Embrace Scar Therapy Device

Standard of Care

PLACEBO COMPARATOR

Another 1/2 of cutaneous wound will be treated per standard of care

Other: Standard of Care

Interventions

Without the embrace Scar Therapy Device

Standard of Care

16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive.

Embrace Scar Therapy Device

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older
  • Able to give informed consent themselves
  • Patient scheduled for cutaneous surgical procedure along a flat surface suitable to application of the embrace with predicted primary closure.
  • Able to apply dressings themselves.
  • Willing to return for follow up visits.

You may not qualify if:

  • Mentally handicapped
  • Unable to understand written and oral English
  • Incarceration
  • Under 18 years of age
  • Pregnant Women
  • Wounds with predicted closure length less than 3 cm
  • Patients with known adverse reactions to adhesives
  • Patients with history of collagen vascular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California, Davis, Department of Dermatology

Sacramento, California, 95816, United States

Location

MeSH Terms

Conditions

Cicatrix

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

FibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Limitations and Caveats

Study terminated early due to poor patient follow-up and insufficient data for analysis. Poor patient follow-up was attributed to the COVID-19 pandemic.

Results Point of Contact

Title
Dr. Daniel Eisen
Organization
UC Davis - Department of Dermatology

Study Officials

  • Daniel B Eisen, MD

    UC Davis

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
FACTORIAL
Model Details: Each subject receives both types of interventions upon the same scar in order for comparison.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 22, 2017

First Posted

September 27, 2017

Study Start

March 15, 2017

Primary Completion

December 1, 2021

Study Completion

December 8, 2025

Last Updated

June 10, 2026

Results First Posted

June 10, 2026

Record last verified: 2026-06

Locations